CA2879538A1 - Production of highly purified sodium hyaluronate (hana) with controlled molecular weight - Google Patents
Production of highly purified sodium hyaluronate (hana) with controlled molecular weight Download PDFInfo
- Publication number
- CA2879538A1 CA2879538A1 CA2879538A CA2879538A CA2879538A1 CA 2879538 A1 CA2879538 A1 CA 2879538A1 CA 2879538 A CA2879538 A CA 2879538A CA 2879538 A CA2879538 A CA 2879538A CA 2879538 A1 CA2879538 A1 CA 2879538A1
- Authority
- CA
- Canada
- Prior art keywords
- cndot
- sodium hyaluronate
- molecular weight
- fermentation
- production
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/46—Streptococcus ; Enterococcus; Lactococcus
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Disclosed is a process for the production of sodium hyaluronate with a molecular weight of between 60 and 2400 kDa and low polydispersity (1.4Mw/Mn), which comprises: a) a step of fermentation of Streptococcus equi subsp. zooepidemicus CNCM I-4645 in a suitable culture medium; b) a step of ultrafiltration of the cell-free filtered solution, by concentrating and diafiltering the solution under differential pressure conditions (?P) of 1.0-5.0 barg and transmembrane pressure (TMP) of 0.5-4 barg.
Description
2 PCT/EP2013/062360 PRODUCTION OF HIGHLY PURIFIED SODIUM HYALURONATE (HANA) WITH CONTROLLED MOLECULAR WEIGHT
ABSTRACT
Disclosed is a method for the production of sodium hyaluronate (HANa) which comprises the growth of a micro-organism of the genus Streptococcus equi subsp. zooepidemicus under suitable conditions in a nutrient medium containing a sugar as the carbon source.
The present invention relates to a process for the production of hyaluronic acid sodium salt which is highly purified by large-scale fermentation of a micro-organism of the genus Streptococcus.
Field of invention The invention relates to processes for the production of highly purified sodium hyaluronate, and in particular to processes including a fermentation step.
By the process according to the invention, HANa is produced in compliance with current purity, safety and consistency standards. To obtain a high degree of purity, a medium containing no ingredients of animal origin is used in the process.
Due to the porosity and small size of its particles, the HANa obtained by the process claimed herein dissolves more rapidly than other HANas of animal and fermentation origin, leading to a considerable reduction in manufacturing time and costs. Moreover, the high purity of the material enables it to be sterilised subsequently without any significant loss of molecular weight. The advantages of this novel manufacturing process are therefore absolute safety, high purity profiles, and low thermolability; rapid dissolution and simple filterability to prepare solutions; and the reproducibility of the molecular weight, which is associated with low polydispersity.
Prior art Hyaluronic acid is a glycosaminoglycan present in nature, which consists of a linear polymer with a molecular weight of 50,000 to 13,000,000 daltons. It is a polysaccharide formed by repeating units of glucuronic acid and N-acetylglucosamine, bonded by alternating 131-3 and 131-4 bonds.
Hyaluronic acid is present in various connective tissues of animals, such as skin and cartilage. Some organs, such as the umbilical cord, synovial fluid, vitreous humour and rooster combs, are particularly rich in hyaluronic acid.
Hyaluronic acid is also produced by various micro-organisms, such as Streptococcus Type A and C. Hyaluronic acid is present in all the body tissues, and performs many important functions. It promotes the release of nutrients and transport of toxins from cells which have no blood supply, such as those located in cartilage; without adequate amounts of HA, the joints would deteriorate and become fragile. Hyaluronic acid not only keeps the joints lubricated, but also stimulates fluid retention in other body tissues.
In the skin and cartilage, the role of hyaluronic acid is to bind to water and preserve the tonicity and elasticity of the tissue. The viscous hyaluronic acid solution in the joint fluids acts as a lubricant, providing a protective environment for the cells.
Due to its hydrophilic nature and its rheological and lubricating properties, sodium hyaluronate is a biopolymer with a high added value which has a wide variety of medical applications, including skin hydration, osteoarthritis treatment, ophthalmic surgery, prevention of adhesions after abdominal surgery, and wound healing.
Novel uses of sodium hyaluronate are drug release, coatings/implants and therapeutic treatments, based on its ability to modify cell behaviour. As
ABSTRACT
Disclosed is a method for the production of sodium hyaluronate (HANa) which comprises the growth of a micro-organism of the genus Streptococcus equi subsp. zooepidemicus under suitable conditions in a nutrient medium containing a sugar as the carbon source.
The present invention relates to a process for the production of hyaluronic acid sodium salt which is highly purified by large-scale fermentation of a micro-organism of the genus Streptococcus.
Field of invention The invention relates to processes for the production of highly purified sodium hyaluronate, and in particular to processes including a fermentation step.
By the process according to the invention, HANa is produced in compliance with current purity, safety and consistency standards. To obtain a high degree of purity, a medium containing no ingredients of animal origin is used in the process.
Due to the porosity and small size of its particles, the HANa obtained by the process claimed herein dissolves more rapidly than other HANas of animal and fermentation origin, leading to a considerable reduction in manufacturing time and costs. Moreover, the high purity of the material enables it to be sterilised subsequently without any significant loss of molecular weight. The advantages of this novel manufacturing process are therefore absolute safety, high purity profiles, and low thermolability; rapid dissolution and simple filterability to prepare solutions; and the reproducibility of the molecular weight, which is associated with low polydispersity.
Prior art Hyaluronic acid is a glycosaminoglycan present in nature, which consists of a linear polymer with a molecular weight of 50,000 to 13,000,000 daltons. It is a polysaccharide formed by repeating units of glucuronic acid and N-acetylglucosamine, bonded by alternating 131-3 and 131-4 bonds.
Hyaluronic acid is present in various connective tissues of animals, such as skin and cartilage. Some organs, such as the umbilical cord, synovial fluid, vitreous humour and rooster combs, are particularly rich in hyaluronic acid.
Hyaluronic acid is also produced by various micro-organisms, such as Streptococcus Type A and C. Hyaluronic acid is present in all the body tissues, and performs many important functions. It promotes the release of nutrients and transport of toxins from cells which have no blood supply, such as those located in cartilage; without adequate amounts of HA, the joints would deteriorate and become fragile. Hyaluronic acid not only keeps the joints lubricated, but also stimulates fluid retention in other body tissues.
In the skin and cartilage, the role of hyaluronic acid is to bind to water and preserve the tonicity and elasticity of the tissue. The viscous hyaluronic acid solution in the joint fluids acts as a lubricant, providing a protective environment for the cells.
Due to its hydrophilic nature and its rheological and lubricating properties, sodium hyaluronate is a biopolymer with a high added value which has a wide variety of medical applications, including skin hydration, osteoarthritis treatment, ophthalmic surgery, prevention of adhesions after abdominal surgery, and wound healing.
Novel uses of sodium hyaluronate are drug release, coatings/implants and therapeutic treatments, based on its ability to modify cell behaviour. As
3 the performance of the product formulated in many of said applications depends on the molecular weight of the biopolymer, the MW represents a characteristic of primary importance in the production of sodium hyaluronate.
There are two main methods of obtaining sodium hyaluronate: (i) extraction of hyaluronic acid from animal tissues (e.g. extraction from rooster combs); (ii) growth of micro-organisms and recovery of hyaluronic acid as a product of fermentation.
(i) Extraction from rooster combs is expensive and time-consuming and leads to serious problems, namely a reduction in quality due to contamination by the enzymes that degrade hyaluronic acid (HAase), and inflammatory reactions at the time of injection. The extraction processes are also characterised by a number of problems and by low yields, limited availability of the starting material, inability to control the characteristics of the end product (such as the molecular weight), and contamination risks deriving from viruses.
(ii) The production of sodium hyaluronate by fermentation of a suitable micro-organism represents an effective process in terms of costs. Numerous methods are described in the literature for the production and purification of sodium hyaluronate using fermentation technology. However, many of them commonly use quaternary ammonium salts to remove impurities, leading to lengthy precipitate re-dissolution times and the presence of quaternary ammonium salts in the end product. Moreover, said purification techniques are mainly based on different precipitation steps requiring extensive use of organic solvents, thus increasing the costs associated with the purification of the product and waste disposal.
US2010/0137579A1 discloses a process for the purification of hyaluronic acid of biological origin (Streptococcus zooepidemicus) which is suitable for medical uses, comprising diafiltration and ultrafiltration steps.
There are two main methods of obtaining sodium hyaluronate: (i) extraction of hyaluronic acid from animal tissues (e.g. extraction from rooster combs); (ii) growth of micro-organisms and recovery of hyaluronic acid as a product of fermentation.
(i) Extraction from rooster combs is expensive and time-consuming and leads to serious problems, namely a reduction in quality due to contamination by the enzymes that degrade hyaluronic acid (HAase), and inflammatory reactions at the time of injection. The extraction processes are also characterised by a number of problems and by low yields, limited availability of the starting material, inability to control the characteristics of the end product (such as the molecular weight), and contamination risks deriving from viruses.
(ii) The production of sodium hyaluronate by fermentation of a suitable micro-organism represents an effective process in terms of costs. Numerous methods are described in the literature for the production and purification of sodium hyaluronate using fermentation technology. However, many of them commonly use quaternary ammonium salts to remove impurities, leading to lengthy precipitate re-dissolution times and the presence of quaternary ammonium salts in the end product. Moreover, said purification techniques are mainly based on different precipitation steps requiring extensive use of organic solvents, thus increasing the costs associated with the purification of the product and waste disposal.
US2010/0137579A1 discloses a process for the purification of hyaluronic acid of biological origin (Streptococcus zooepidemicus) which is suitable for medical uses, comprising diafiltration and ultrafiltration steps.
4 The publication Biopolymers, 2010, 387-412 describes a process for the biotechnological production of hyaluronic acid by fermentation of Streptococcus zooepidermicus, filtration through a carbon filter, ultrafiltration/diafiltration and sterilisation by microfiltration.
Separation and Purification Technology, 2006, 52, 29-38 describes a two-step tangential flow filtration process for the separation of hyaluronic acid from a fermentation broth. However, this method is not suitable for large-scale production of hyaluronic acid, and the latter does not reach a purity suitable for medical uses.
In view of the problems associated with the methods described, the importance of a sodium hyaluronate manufacturing process which is simple, easily applicable and able to remove impurities such as proteins, nucleic acids, endotoxins, metal ions, etc., is clear.
Description of the invention The invention relates to a process for the production of sodium hyaluronate with high yields by fermentation of Streptococcus bacteria under aerobic conditions in a growth medium enriched with a flow of air, subsequent separation of the bacteria from the resulting culture broth, and isolation of sodium hyaluronate from the culture broth.
Detailed description of the invention The present invention overcomes the above-mentioned problems with a process for the production of highly purified sodium hyaluronate by fermentation in a suitable nutrient medium under appropriate conditions, using a micro-organism of the species Streptococcus equi, sub-sp. zooepidemicus (mutant strain deriving from wild-type strain DSM no. 20727). The mutant strain was deposited under CNCM number 1-4645 on 21.06.2012 in the Pasteur Institute's Collection Nationale de Cultures de Microorganismes (Paris).
During fermentation, the micro-organism produces hyaluronic acid, and releases it into the culture medium.
Hyaluronic acid is then recovered from the fermentation medium by reducing the viscosity of the solution with an acid, concentrating and
Separation and Purification Technology, 2006, 52, 29-38 describes a two-step tangential flow filtration process for the separation of hyaluronic acid from a fermentation broth. However, this method is not suitable for large-scale production of hyaluronic acid, and the latter does not reach a purity suitable for medical uses.
In view of the problems associated with the methods described, the importance of a sodium hyaluronate manufacturing process which is simple, easily applicable and able to remove impurities such as proteins, nucleic acids, endotoxins, metal ions, etc., is clear.
Description of the invention The invention relates to a process for the production of sodium hyaluronate with high yields by fermentation of Streptococcus bacteria under aerobic conditions in a growth medium enriched with a flow of air, subsequent separation of the bacteria from the resulting culture broth, and isolation of sodium hyaluronate from the culture broth.
Detailed description of the invention The present invention overcomes the above-mentioned problems with a process for the production of highly purified sodium hyaluronate by fermentation in a suitable nutrient medium under appropriate conditions, using a micro-organism of the species Streptococcus equi, sub-sp. zooepidemicus (mutant strain deriving from wild-type strain DSM no. 20727). The mutant strain was deposited under CNCM number 1-4645 on 21.06.2012 in the Pasteur Institute's Collection Nationale de Cultures de Microorganismes (Paris).
During fermentation, the micro-organism produces hyaluronic acid, and releases it into the culture medium.
Hyaluronic acid is then recovered from the fermentation medium by reducing the viscosity of the solution with an acid, concentrating and
5 purifying it, for example by ultrafiltration, checking and defining the molecular weight with a heat treatment with low pH values, further purification by adsorption with a suitable adsorption technique, precipitating sodium hyaluronate, for example by precipitation with organic solvents, filtering and drying the precipitate.
The scheme schematically illustrates the process according to the present invention.
According to the invention, "high-molecular-weight sodium hyaluronate" means a sodium hyaluronate having an intrinsic viscosity >
1.8 m3/Kg.
The micro-organism is grown in a bioreactor, in a suitable culture medium, under high stirring and aeration speed conditions.
The medium contains a sugar as the carbon source at a starting concentration ranging from 20 to 80 grams per litre, and 20 to 30 grams per litre of yeast extract and/or soya peptone.
The pH of the medium is kept constant in the 6.0 to 8.0 interval by continuous addition of a basic solution managed by a pH controller; the pH of the medium is preferably maintained at about 7.0 by continual addition of concentrated NaOH.
The growth of the bacteria is carried out under pressurised aerobic conditions, preferably with a high stirring speed. The air pressure is kept constant at about 0.6-1.0 bar gauge, and the aeration at about 0.8-1.2 air volumes per medium volume per minute.
The fermentation yields range from 5.0 to 10 0:1 of sodium
The scheme schematically illustrates the process according to the present invention.
According to the invention, "high-molecular-weight sodium hyaluronate" means a sodium hyaluronate having an intrinsic viscosity >
1.8 m3/Kg.
The micro-organism is grown in a bioreactor, in a suitable culture medium, under high stirring and aeration speed conditions.
The medium contains a sugar as the carbon source at a starting concentration ranging from 20 to 80 grams per litre, and 20 to 30 grams per litre of yeast extract and/or soya peptone.
The pH of the medium is kept constant in the 6.0 to 8.0 interval by continuous addition of a basic solution managed by a pH controller; the pH of the medium is preferably maintained at about 7.0 by continual addition of concentrated NaOH.
The growth of the bacteria is carried out under pressurised aerobic conditions, preferably with a high stirring speed. The air pressure is kept constant at about 0.6-1.0 bar gauge, and the aeration at about 0.8-1.2 air volumes per medium volume per minute.
The fermentation yields range from 5.0 to 10 0:1 of sodium
6 hyaluronate with an average molecular weight ranging from about 1.8 to about 3.0x106 daltons.
The duration of fermentation is about 7-12 hours, with a 1 to 5% v/v inoculum grown to 4.0-12.0 OD units measured at 600 nm. At the end of fermentation, the density of the biomass is equivalent to a turbidity of 8-16 OD units.
The most suitable culture medium has the following composition:
Sucrose 60 - 80 g=L1 -Glucose 20 - 60 g=L1 -Yeast extract 20 - 30 g=L-1 Peptone 10 - 30 g=L-Monobasic sodium phosphate monohydrate 2.0 - 4.0 g=L-1 Magnesium sulphate heptahydrate 1.0 - 3.0 g=L-1 Potassium sulphate 0.5 - 2.2 g=L1 -Non-silicone antifoaming agent 0.2 - 1.0 g=L-1 Calcium chloride hexahydrate 8.0 - 12.0 mg=L1 -Manganese sulphate monohydrate 0.05 - 0.2 mg=L-1 Copper sulphate pentahydrate 0.01 -0.1 mg.L1 -Zinc chloride 0.05 - 0.2 mg=L1 -L-Arginine 40.0 - 60.0 mg=L-1 Monosodium glutamate 2.0 - 6.0 g=L1 -Sodium hyaluronate can be recovered by treating the medium to remove the micro-organism and other materials insoluble in the medium. The preferred method of removal, after adding acid to reduce the viscosity of the solution, is filtration with an inert filtration aid.
Sodium hyaluronate is then microfiltered through filter cartridges with a nominal rating of 0.6/0.2 micrometres (lim) to remove any residues of the filtration aid and the micro-organism.
The duration of fermentation is about 7-12 hours, with a 1 to 5% v/v inoculum grown to 4.0-12.0 OD units measured at 600 nm. At the end of fermentation, the density of the biomass is equivalent to a turbidity of 8-16 OD units.
The most suitable culture medium has the following composition:
Sucrose 60 - 80 g=L1 -Glucose 20 - 60 g=L1 -Yeast extract 20 - 30 g=L-1 Peptone 10 - 30 g=L-Monobasic sodium phosphate monohydrate 2.0 - 4.0 g=L-1 Magnesium sulphate heptahydrate 1.0 - 3.0 g=L-1 Potassium sulphate 0.5 - 2.2 g=L1 -Non-silicone antifoaming agent 0.2 - 1.0 g=L-1 Calcium chloride hexahydrate 8.0 - 12.0 mg=L1 -Manganese sulphate monohydrate 0.05 - 0.2 mg=L-1 Copper sulphate pentahydrate 0.01 -0.1 mg.L1 -Zinc chloride 0.05 - 0.2 mg=L1 -L-Arginine 40.0 - 60.0 mg=L-1 Monosodium glutamate 2.0 - 6.0 g=L1 -Sodium hyaluronate can be recovered by treating the medium to remove the micro-organism and other materials insoluble in the medium. The preferred method of removal, after adding acid to reduce the viscosity of the solution, is filtration with an inert filtration aid.
Sodium hyaluronate is then microfiltered through filter cartridges with a nominal rating of 0.6/0.2 micrometres (lim) to remove any residues of the filtration aid and the micro-organism.
7 The pH of the medium is then adjusted to about 7.0 by adding concentrated NaOH.
The filtrate, treated with the inert filtration aid, undergoes tangential flow filtration (TFF) to remove the residual ingredients with low molecular weight deriving from the fermentation step. The ultrafiltration treatment is performed with ultrafiltration membranes with a cut-off of 10-100 KDa, with highly purified water (HPW) as diafiltration buffer.
The diafiltered solution is then subjected to heat treatment with the addition of hydrochloric acid (2M) to reduce its molecular weight and intrinsic viscosity. At the end of the heat treatment the pH of the solution is adjusted to 7.0 1.0 by adding concentrated NaOH.
The product thus obtained, after the addition of sodium chloride (normally 0.7 M), is purified with a suitable filtration aid and then filtered.
The filtrate is then microfiltered through filter cartridges with a nominal rating of 0.2 micrometres (um).
After the addition of hydrochloric acid (HC1), sodium hyaluronate can be precipitated with an organic solvent such as 96% v/v ethanol. After removal of the supernatant, 96% v/v ethanol is added to the precipitate. After removal of the supernatant, 96% v/v ethanol is added to this second precipitate. The precipitate thus recovered is then dried under vacuum to obtain a fine sodium hyaluronate powder. If desired, sodium hyaluronate can be produced with a defined molecular weight and intrinsic viscosity by conducting a heat treatment at low pH values according to the table set out below:
The filtrate, treated with the inert filtration aid, undergoes tangential flow filtration (TFF) to remove the residual ingredients with low molecular weight deriving from the fermentation step. The ultrafiltration treatment is performed with ultrafiltration membranes with a cut-off of 10-100 KDa, with highly purified water (HPW) as diafiltration buffer.
The diafiltered solution is then subjected to heat treatment with the addition of hydrochloric acid (2M) to reduce its molecular weight and intrinsic viscosity. At the end of the heat treatment the pH of the solution is adjusted to 7.0 1.0 by adding concentrated NaOH.
The product thus obtained, after the addition of sodium chloride (normally 0.7 M), is purified with a suitable filtration aid and then filtered.
The filtrate is then microfiltered through filter cartridges with a nominal rating of 0.2 micrometres (um).
After the addition of hydrochloric acid (HC1), sodium hyaluronate can be precipitated with an organic solvent such as 96% v/v ethanol. After removal of the supernatant, 96% v/v ethanol is added to the precipitate. After removal of the supernatant, 96% v/v ethanol is added to this second precipitate. The precipitate thus recovered is then dried under vacuum to obtain a fine sodium hyaluronate powder. If desired, sodium hyaluronate can be produced with a defined molecular weight and intrinsic viscosity by conducting a heat treatment at low pH values according to the table set out below:
8 Molecular weight Intrinsic Niscosity (n-i'=kg-I
(KDa) ) pH (UpH) 60 - 100 0.14 - 0.29 1.00 - 3.00 100 - 250 0.29 - 0.68 1.00 - 3.00 250 -350 0.68 - 0.88 2.00 - 4.00 350 - 500 0.88 - 1.12 2.00 - 4.00 500 - 800 1.2 - 1.52 2.00 - 4.00 800- 1000 1.52- 1.75 3.00 - 5.00 1000 - 1400 1.75 - 2.14 3.00 - 5.00 1400- 1800 2.14 - 2.47 3.00- 5.00 1800 - 2400 2.47 - 2.92 3.00 - 5.00 The invention will be described in greater detail in the following example.
Example Selection of bacteria for high-yield production Streptococcus equi subsp. zooepidemicus CNCM 1-4645 (mutant strain deriving from wild-type strain DSM number 20727, deposited in the DSMZ
Microbial Collection) is used as HANa producing bacterium: the micro-organism is stored in 20% (v/v) glycerol in a vial and frozen (T<-70 C).
The manufacturing process begins with thawing of a vial followed by streaking of the bacterial suspension in the plate on solid medium, and growth at 37 C for 20-36 hours (Revitalisation Step). A colony taken from the plate is then resuspended in fresh culture medium in a test tube and incubated for 8-16 hours at 37 C under stirring (100-300 rpm, Cell Expansion Step I). The test tube is then used as inoculum in two 5-litre Erlenmeyer flasks containing 2 litres of sterile culture medium. The flasks are incubated for 8-16 hours at 37 C under stirring (100-300 rpm, Cell Expansion Step II). The cell suspension obtained is then used for inoculation.
(KDa) ) pH (UpH) 60 - 100 0.14 - 0.29 1.00 - 3.00 100 - 250 0.29 - 0.68 1.00 - 3.00 250 -350 0.68 - 0.88 2.00 - 4.00 350 - 500 0.88 - 1.12 2.00 - 4.00 500 - 800 1.2 - 1.52 2.00 - 4.00 800- 1000 1.52- 1.75 3.00 - 5.00 1000 - 1400 1.75 - 2.14 3.00 - 5.00 1400- 1800 2.14 - 2.47 3.00- 5.00 1800 - 2400 2.47 - 2.92 3.00 - 5.00 The invention will be described in greater detail in the following example.
Example Selection of bacteria for high-yield production Streptococcus equi subsp. zooepidemicus CNCM 1-4645 (mutant strain deriving from wild-type strain DSM number 20727, deposited in the DSMZ
Microbial Collection) is used as HANa producing bacterium: the micro-organism is stored in 20% (v/v) glycerol in a vial and frozen (T<-70 C).
The manufacturing process begins with thawing of a vial followed by streaking of the bacterial suspension in the plate on solid medium, and growth at 37 C for 20-36 hours (Revitalisation Step). A colony taken from the plate is then resuspended in fresh culture medium in a test tube and incubated for 8-16 hours at 37 C under stirring (100-300 rpm, Cell Expansion Step I). The test tube is then used as inoculum in two 5-litre Erlenmeyer flasks containing 2 litres of sterile culture medium. The flasks are incubated for 8-16 hours at 37 C under stirring (100-300 rpm, Cell Expansion Step II). The cell suspension obtained is then used for inoculation.
9 Production fermentation After inoculation into the sterile culture medium, the production fermentation is carried out at 30-40 C and pH 7.0 1.0 with aeration of 1500 L=min 1, overpressure of 0.6-1.0 bar gauge, and stirring at 200-300 rpm.
The pH value is kept constant in the specific range by adding concentrated NaOH. During fermentation, hyaluronic acid forms as part of the cell capsule, and is gradually released in soluble form into the fermentation medium.
Filtration and microfiltration The fermentation culture broth is transferred to a tank where an acid is added to make it less viscous, and an inert filtration aid is added to obtain the higher rate of flow necessary for the required degree of clarification. When the packing step has been completed, the cell suspension is conveyed by a pump to a pressurised filter and filtered; the panel that forms is retained by the filter plates, while the filtrate is recovered for the subsequent steps.
The product thus obtained is microfiltered to remove any aid or cell residues by filtering it, with normal flow filtration (NFF), through filter cartridges with a nominal rating of 0.6/0.2 micrometres (um).
Neutralisation and ultrafiltration After the filtration and microfiltration (MF) steps, a cell-free filtered solution of sodium hyaluronate is obtained, which can be purified. The first step is to collect the product in a storage tank to which concentrated NaOH is added to restore the pH value to about 7.
A membrane tangential flow ultrafiltration (TFF) system is used to concentrate and purify the product. The membranes used (cassettes or hollow fibre modules) are made of a material compatible with the process, preferably polyethersulphone or polypropylene, and have a cut-off of 10-100 kDa, preferably 30 kDa. The operating intervals of the ultrafiltration process parameters are: trans-membrane pressure (TMP) 0.5-4.5 barg and differential pressure (AP) 1.0-5.0 barg. The supernatant is concentrated up to 3-5 times the initial volume to eliminate the majority of low-molecular-weight contaminants. The retentate containing sodium hyaluronate is diafiltered up to 5-7 volumes with highly purified water to remove the remaining 5 low-molecular-weight contaminants. The diafiltration terminates when a conductivity value below 300 liS=cm-1 is reached.
Heat treatment at low pH values and neutralisation The concentrated, diafiltered product is heated under stirring in a process tank thermostated in a temperature range of 50-65 C, and the pH is
The pH value is kept constant in the specific range by adding concentrated NaOH. During fermentation, hyaluronic acid forms as part of the cell capsule, and is gradually released in soluble form into the fermentation medium.
Filtration and microfiltration The fermentation culture broth is transferred to a tank where an acid is added to make it less viscous, and an inert filtration aid is added to obtain the higher rate of flow necessary for the required degree of clarification. When the packing step has been completed, the cell suspension is conveyed by a pump to a pressurised filter and filtered; the panel that forms is retained by the filter plates, while the filtrate is recovered for the subsequent steps.
The product thus obtained is microfiltered to remove any aid or cell residues by filtering it, with normal flow filtration (NFF), through filter cartridges with a nominal rating of 0.6/0.2 micrometres (um).
Neutralisation and ultrafiltration After the filtration and microfiltration (MF) steps, a cell-free filtered solution of sodium hyaluronate is obtained, which can be purified. The first step is to collect the product in a storage tank to which concentrated NaOH is added to restore the pH value to about 7.
A membrane tangential flow ultrafiltration (TFF) system is used to concentrate and purify the product. The membranes used (cassettes or hollow fibre modules) are made of a material compatible with the process, preferably polyethersulphone or polypropylene, and have a cut-off of 10-100 kDa, preferably 30 kDa. The operating intervals of the ultrafiltration process parameters are: trans-membrane pressure (TMP) 0.5-4.5 barg and differential pressure (AP) 1.0-5.0 barg. The supernatant is concentrated up to 3-5 times the initial volume to eliminate the majority of low-molecular-weight contaminants. The retentate containing sodium hyaluronate is diafiltered up to 5-7 volumes with highly purified water to remove the remaining 5 low-molecular-weight contaminants. The diafiltration terminates when a conductivity value below 300 liS=cm-1 is reached.
Heat treatment at low pH values and neutralisation The concentrated, diafiltered product is heated under stirring in a process tank thermostated in a temperature range of 50-65 C, and the pH is
10 adjusted to the value of 1-5 UpH by adding hydrochloric acid. The solution is then incubated under said conditions until the required molecular weight is obtained. Under these conditions, the sodium hyaluronate molecules break down at random without forming by-products. The heat treatment is terminated by adjusting the pH to a value of 7.0 1.0 UpH with concentrated NaOH and cooling to a temperature of about 25.0 C.
Adsorption with activated carbon, filtration and polishing A salt is added to the ultrafiltered solution to reduce its viscosity, and a filtration aid is used to remove endotoxins. To remove the endotoxins effectively, the solution is stirred for at least 2-4 hours and then filtered to remove the filtration aid. The filtrate is microfiltered by normal flow filtration to eliminate any residues of filtration aid.
Precipitation After adding hydrochloric acid (e.g. 2M) to neutralise the solution, an organic solvent (such as 96% v/v ethanol) is added to the sodium hyaluronate solution. The water-soluble organic solvent is preferably added in the range of 1.2-2.8 volumes of the sodium hyaluronate solution. To precipitate and sediment sodium hyaluronate effectively by adding an organic solvent to the sodium hyaluronate solution, it is preferable to leave it to sediment for at least
Adsorption with activated carbon, filtration and polishing A salt is added to the ultrafiltered solution to reduce its viscosity, and a filtration aid is used to remove endotoxins. To remove the endotoxins effectively, the solution is stirred for at least 2-4 hours and then filtered to remove the filtration aid. The filtrate is microfiltered by normal flow filtration to eliminate any residues of filtration aid.
Precipitation After adding hydrochloric acid (e.g. 2M) to neutralise the solution, an organic solvent (such as 96% v/v ethanol) is added to the sodium hyaluronate solution. The water-soluble organic solvent is preferably added in the range of 1.2-2.8 volumes of the sodium hyaluronate solution. To precipitate and sediment sodium hyaluronate effectively by adding an organic solvent to the sodium hyaluronate solution, it is preferable to leave it to sediment for at least
11 3-7 hours after adding the organic solvent.
The precipitated sodium hyaluronate obtained at this step, from removal of the supernatant, is washed by adding fresh organic solvent. The sodium hyaluronate precipitate obtained at this second step, after removal of the supernatant, is resuspended in fresh organic solvent.
Recovery and drying The sedimented sodium hyaluronate is recovered and filtered. A final drying step is performed under vacuum to obtain a very fine powder.
Sodium hyaluronate thus obtained is suitable to produce preparations characterised by the absence of pyrogenicity and inflammatory activity.
The precipitated sodium hyaluronate obtained at this step, from removal of the supernatant, is washed by adding fresh organic solvent. The sodium hyaluronate precipitate obtained at this second step, after removal of the supernatant, is resuspended in fresh organic solvent.
Recovery and drying The sedimented sodium hyaluronate is recovered and filtered. A final drying step is performed under vacuum to obtain a very fine powder.
Sodium hyaluronate thus obtained is suitable to produce preparations characterised by the absence of pyrogenicity and inflammatory activity.
12 Scheme Inoculum Fermentation I
- Acid Collection of - Filtration -ii.
fermentation broth adjuvant Primary filtration of fermentation broth with filtration adjuvant /
Concentration and diafiltration by tangential flow filtration (T14) - Acid- Heat treatment at low pH values and - NaOH neutralisation - Filtration adjuvant -11. Adsorption vir Filtration Polishing - HCI Precipitation with organic solvent Recovery and drying Packaging
- Acid Collection of - Filtration -ii.
fermentation broth adjuvant Primary filtration of fermentation broth with filtration adjuvant /
Concentration and diafiltration by tangential flow filtration (T14) - Acid- Heat treatment at low pH values and - NaOH neutralisation - Filtration adjuvant -11. Adsorption vir Filtration Polishing - HCI Precipitation with organic solvent Recovery and drying Packaging
13 PCT
Print Out (Original in Electronic Form) (This sheet is not part of and does not count as a sheet of the international application) 0-1 Form PCT/RO/134 (SAFE) Indications Relating to Deposited Microorganism(s) or Other Biological Material (PCT Rule 13bis) 0-1-1 Prepared Using PCT Online Filing Version 3.5.000.235 MT/FOP
20020701/0.20.5.20 0-2 International Application No.
0-3 Applicant's or agent's file reference SCB 1483 PCT
1 The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:
1-1 page 8 1-2 line 5-7 1-3 Identification of deposit 1-3-1 Name of depositary institution CNCM Collection nationale de cultures de micro -organismes 1-3-2 Address of depositary institution Institut Pasteur, 28, rue du Dr Roux, 75724 Paris Cedex 15, France 1-3-3 Date of deposit 21 June 2012 (21.06.2012) 1-3-4 Accession Number CNCM 1-4645 1-5 Designated States for Which All designations Indications are Made FOR RECEIVING OFFICE USE ONLY
0-4 This form was received with the international application: yes (yes or no) 0-4-1 Authorized officer Pasche, Constantinus FOR INTERNATIONAL BUREAU USE ONLY
0-5 This form was received by the international Bureau on:
0-5-1 Authorized officer
Print Out (Original in Electronic Form) (This sheet is not part of and does not count as a sheet of the international application) 0-1 Form PCT/RO/134 (SAFE) Indications Relating to Deposited Microorganism(s) or Other Biological Material (PCT Rule 13bis) 0-1-1 Prepared Using PCT Online Filing Version 3.5.000.235 MT/FOP
20020701/0.20.5.20 0-2 International Application No.
0-3 Applicant's or agent's file reference SCB 1483 PCT
1 The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:
1-1 page 8 1-2 line 5-7 1-3 Identification of deposit 1-3-1 Name of depositary institution CNCM Collection nationale de cultures de micro -organismes 1-3-2 Address of depositary institution Institut Pasteur, 28, rue du Dr Roux, 75724 Paris Cedex 15, France 1-3-3 Date of deposit 21 June 2012 (21.06.2012) 1-3-4 Accession Number CNCM 1-4645 1-5 Designated States for Which All designations Indications are Made FOR RECEIVING OFFICE USE ONLY
0-4 This form was received with the international application: yes (yes or no) 0-4-1 Authorized officer Pasche, Constantinus FOR INTERNATIONAL BUREAU USE ONLY
0-5 This form was received by the international Bureau on:
0-5-1 Authorized officer
Claims (6)
1. Process for the manufacture of sodium hyaluronate with defined molecular weight ranging from 60 to 2400 kDa and low polydispersity (1.4Mw/Mn) which comprises:
a) a fermentation step of Streptococcus equi subsp. zooepidemicus CNCM I-4645 in a suitable culture medium;
b) an ultrafiltration step of the cell-free filtered solution, concentrating and diafiltering the solution in differential pressure conditions (.DELTA.P) from 1.0 to 5.0 barg and at transmembrane pressure (TMP) from 0.5 to 4.5 barg.
a) a fermentation step of Streptococcus equi subsp. zooepidemicus CNCM I-4645 in a suitable culture medium;
b) an ultrafiltration step of the cell-free filtered solution, concentrating and diafiltering the solution in differential pressure conditions (.DELTA.P) from 1.0 to 5.0 barg and at transmembrane pressure (TMP) from 0.5 to 4.5 barg.
2. Process according to claim 1 wherein the fermentation step is carried out in batch procedure to give the maximum concentration of hyaluronic acid (5 - 10.cndot.L -1) after 7 - 12 hours.
3. Process according to claims 1 and 2 wherein the fermentation step is carried out in aerobic conditions at the pressure of 0.6 - 1.0 bar gauge and an aeration condition of about 0.8 - 1.2 volumes of air per volume of medium per minute.
4. Process according to claims 1 to 3, wherein the culture medium has the following composition:
Sucrose 60 - 80 g.cndot.L -1 Glucose 20 - 60 g.cndot.L -1 Yeast extract 20 - 30 g.cndot.L -1 Peptone 10 - 30 g.cndot.L -1 Monobasic sodium phosphate monohydrate 2.0 - 4.0 g.cndot.L -1 Magnesium sulphate heptahydrate 1.0 - 3.0 g.cndot.L -1 Potassium sulphate 0.5 - 2.2 g.cndot.L -1 Non-silicone antifoam 0.2 - 1.0 g.cndot.L -1 Calcium chloride hexahydrate 8.0 - 12.0 mg.cndot.L -1 Manganese sulphate monohydrate 0.05 - 0.2 mg.cndot.L -1 Copper sulphate pentahydrate 0.01 -0.1 mg.cndot.L -1 Zinc chloride 0.05 - 0.2 mg.cndot.L -1 L-arginine 40.0 - 60.0 mg.cndot.L -1 Sodium glutamate 2.0 - 6.0 g.cndot.L -1
Sucrose 60 - 80 g.cndot.L -1 Glucose 20 - 60 g.cndot.L -1 Yeast extract 20 - 30 g.cndot.L -1 Peptone 10 - 30 g.cndot.L -1 Monobasic sodium phosphate monohydrate 2.0 - 4.0 g.cndot.L -1 Magnesium sulphate heptahydrate 1.0 - 3.0 g.cndot.L -1 Potassium sulphate 0.5 - 2.2 g.cndot.L -1 Non-silicone antifoam 0.2 - 1.0 g.cndot.L -1 Calcium chloride hexahydrate 8.0 - 12.0 mg.cndot.L -1 Manganese sulphate monohydrate 0.05 - 0.2 mg.cndot.L -1 Copper sulphate pentahydrate 0.01 -0.1 mg.cndot.L -1 Zinc chloride 0.05 - 0.2 mg.cndot.L -1 L-arginine 40.0 - 60.0 mg.cndot.L -1 Sodium glutamate 2.0 - 6.0 g.cndot.L -1
5. Process according to claims 1 to 4 wherein sodium hyaluronate is produced with a predefined molecular weight and intrinsic viscosity by carrying out heat treatment at low pH values according to the following table:
Molecular weight Intrinsic Viscosity pH
(KDa) (m3.cndot.kg -1) (UpH) 60 - 100 0.14 - 0.29 1.00 - 3.00 100 - 250 0.29 - 0.68 1.00 - 3.00 250 -350 0.68 - 0.88 2.00 - 4.00 350 - 500 0.88 - 1.12 2.00 - 4.00 500 - 800 1.2 - 1.52 2.00 - 4.00 800 - 1000 1.52 - 1.75 3.00 - 5.00 1000 - 1400 1.75 - 2.14 3.00 - 5.00 1400 - 1800 2.14 - 2.47 3.00 - 5.00 1800 - 2400 2.47 - 2.92 3.00 - 5.00
Molecular weight Intrinsic Viscosity pH
(KDa) (m3.cndot.kg -1) (UpH) 60 - 100 0.14 - 0.29 1.00 - 3.00 100 - 250 0.29 - 0.68 1.00 - 3.00 250 -350 0.68 - 0.88 2.00 - 4.00 350 - 500 0.88 - 1.12 2.00 - 4.00 500 - 800 1.2 - 1.52 2.00 - 4.00 800 - 1000 1.52 - 1.75 3.00 - 5.00 1000 - 1400 1.75 - 2.14 3.00 - 5.00 1400 - 1800 2.14 - 2.47 3.00 - 5.00 1800 - 2400 2.47 - 2.92 3.00 - 5.00
6. Streptococcus equi subsp. zooepidemicus CNCM I-4645.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT001184A ITMI20121184A1 (en) | 2012-07-05 | 2012-07-05 | PROCESS FOR INDUSTRIAL PRODUCTION OF SODIUM IALURONATE (HANA) HIGHLY PURIFIED WITH CONTROLLED MOLECULAR WEIGHT |
| ITMI2012A001184 | 2012-07-05 | ||
| PCT/EP2013/062360 WO2014005822A1 (en) | 2012-07-05 | 2013-06-14 | Production of highly purified sodium hyaluronate (hana) with controlled molecular weight |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2879538A1 true CA2879538A1 (en) | 2014-01-09 |
| CA2879538C CA2879538C (en) | 2019-12-31 |
Family
ID=46982672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2879538A Active CA2879538C (en) | 2012-07-05 | 2013-06-14 | Production of highly purified sodium hyaluronate (hana) with controlled molecular weight |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9347079B2 (en) |
| EP (1) | EP2870255B1 (en) |
| CN (1) | CN104662158B (en) |
| CA (1) | CA2879538C (en) |
| ES (1) | ES2571584T3 (en) |
| HK (1) | HK1206788A1 (en) |
| HU (1) | HUE029596T2 (en) |
| IT (1) | ITMI20121184A1 (en) |
| PL (1) | PL2870255T3 (en) |
| WO (1) | WO2014005822A1 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105949478B (en) * | 2016-05-05 | 2021-10-01 | 宜昌东阳光生化制药有限公司 | Method for removing cross-linking agent in cross-linked hyaluronic acid |
| IT201600079633A1 (en) * | 2016-07-28 | 2018-01-28 | Fidia Farm Spa | Preparation and purification process of the sodium salt of hyaluronic acid |
| KR101784864B1 (en) | 2016-10-07 | 2017-10-12 | (주)진우바이오 | Streptococcus equi sub. zooepidemicus kdk0001 and Preparing Method for High Molecular Weight Hyaluronic Acid Using the same |
| CN106834387A (en) * | 2017-02-12 | 2017-06-13 | 江苏诚信药业有限公司 | A kind of method for preparing sodium hyaluronate |
| GB201703850D0 (en) * | 2017-03-10 | 2017-04-26 | Givaudan Sa | Improvements in or relating to organic compounds |
| CN107338201B (en) * | 2017-06-23 | 2021-02-02 | 浙江工业大学 | Streptococcus equi subsp zooepidemicus SXY36 and application thereof in fermentation production of hyaluronic acid |
| IT201700081449A1 (en) * | 2017-07-18 | 2019-01-18 | Fidia Farm Spa | PURIFICATION PROCEDURE OF HYALURONIC ACID |
| US11324854B2 (en) | 2017-11-17 | 2022-05-10 | Altergon Sa | Resorbable implantable device based on crosslinked glycosaminoglycans, and process for the preparation thereof |
| CN108611387B (en) * | 2018-05-07 | 2020-09-08 | 山东焦点生物科技股份有限公司 | Method for producing pharmaceutical-grade sodium hyaluronate by utilizing plant peptone |
| CN108992369B (en) * | 2018-07-02 | 2021-07-30 | 山东天晟生物科技有限公司 | Hyaluronic acid, preparation method and application thereof |
| IT201800007683A1 (en) | 2018-07-31 | 2020-01-31 | Altergon Sa | Synergistic cooperative compositions useful for soft tissue augmentation, drug release and related fields |
| CN109295132A (en) * | 2018-10-12 | 2019-02-01 | 上海景峰制药有限公司 | A kind of culture medium and preparation method thereof producing sodium hyaluronate |
| CN109161571A (en) * | 2018-10-12 | 2019-01-08 | 上海景峰制药有限公司 | A kind of culture medium and preparation method thereof for producing Sodium Hyaluronate |
| CN109439584A (en) * | 2018-11-15 | 2019-03-08 | 广东省农业科学院农业生物基因研究中心 | A method of quickly recycling Bacillus coli cells from escherichia coli fermented broth |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7091008B1 (en) * | 1994-07-01 | 2006-08-15 | The Board Of Regents Of The University Of Oklahoma | Hyaluronan synthase genes and expression thereof in Bacillus hosts |
| DE69734205T2 (en) * | 1996-10-10 | 2006-07-06 | Neose Technologies, Inc. | CLEANING OF CARBOHYDRATES BY MEANS OF REVERSE OSMOSIS AND NANOFILTRATION |
| AU2007298454B2 (en) * | 2006-07-06 | 2014-01-16 | Reliance Life Sciences Pvt Ltd | Efficient process for purification of high molecular weight hyaluronic acid |
| WO2010010631A1 (en) * | 2008-07-25 | 2010-01-28 | 電気化学工業株式会社 | Method for producing hyaluronic acid |
| US20100137579A1 (en) * | 2008-12-01 | 2010-06-03 | Sustineo Biotechnology Co., Ltd. | Process for purifying medical grade hyaluronic acid |
| CN101550199B (en) * | 2009-05-09 | 2013-05-15 | 山东众山生物科技有限公司 | Method for preparing sodium hyaluronate from hyaluronic acid zymotic fluid |
| CN101935678B (en) * | 2009-06-30 | 2014-03-26 | 上海佰加壹医药有限公司 | Method for producing hyaluronic acid fermentation liquor |
| SK50752009A3 (en) * | 2009-12-17 | 2011-07-06 | Contipro C A S | Genetically modified strain Streptococcus equi subsp. zooepidemicus producing increased amount of hyalurone acid |
| JP2012191901A (en) * | 2011-03-17 | 2012-10-11 | Mitsubishi Rayon Co Ltd | Stirring type culture tank |
| CN102242165A (en) * | 2011-05-26 | 2011-11-16 | 上海应用技术学院 | Method for producing high molecular weight sodium hyaluronate through fermentation and culture medium utilized by same |
-
2012
- 2012-07-05 IT IT001184A patent/ITMI20121184A1/en unknown
-
2013
- 2013-06-14 US US14/412,448 patent/US9347079B2/en active Active
- 2013-06-14 PL PL13734680T patent/PL2870255T3/en unknown
- 2013-06-14 CA CA2879538A patent/CA2879538C/en active Active
- 2013-06-14 WO PCT/EP2013/062360 patent/WO2014005822A1/en active Application Filing
- 2013-06-14 EP EP13734680.5A patent/EP2870255B1/en active Active
- 2013-06-14 HU HUE13734680A patent/HUE029596T2/en unknown
- 2013-06-14 ES ES13734680T patent/ES2571584T3/en active Active
- 2013-06-14 CN CN201380035588.8A patent/CN104662158B/en active Active
-
2015
- 2015-08-03 HK HK15107415.5A patent/HK1206788A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2870255B1 (en) | 2016-04-06 |
| PL2870255T3 (en) | 2016-07-29 |
| EP2870255A1 (en) | 2015-05-13 |
| HK1206788A1 (en) | 2016-01-15 |
| ES2571584T3 (en) | 2016-05-26 |
| CN104662158B (en) | 2018-02-16 |
| CA2879538C (en) | 2019-12-31 |
| WO2014005822A1 (en) | 2014-01-09 |
| US9347079B2 (en) | 2016-05-24 |
| HUE029596T2 (en) | 2017-03-28 |
| ITMI20121184A1 (en) | 2014-01-06 |
| US20150152459A1 (en) | 2015-06-04 |
| CN104662158A (en) | 2015-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2879538C (en) | Production of highly purified sodium hyaluronate (hana) with controlled molecular weight | |
| DK173681B1 (en) | Process for producing hyaluronic acid from a hyaluronic acid-producing streptococ bacterium | |
| CN102459625B (en) | Biotechnological production of chondroitin | |
| CN101512006B (en) | Efficient process for purification of high molecular weight hyaluronic acid | |
| HU198101B (en) | Process for producing xanthomonas heteropolysaccharide | |
| CN101914169A (en) | Process for purifying hyaluronic acid | |
| CN102242165A (en) | Method for producing high molecular weight sodium hyaluronate through fermentation and culture medium utilized by same | |
| JP4802821B2 (en) | Process for producing purified β-D-glucan | |
| KR20110029492A (en) | Method of molecular weight control of hyaluronic acid | |
| TWI504611B (en) | Hyaluronic acid and / or a salt thereof | |
| JP5969390B2 (en) | Fucose-containing bacterial biopolymer | |
| CN111778303B (en) | Method for degrading hyaluronic acid or salt thereof by enzyme | |
| CN109234328B (en) | Method for producing gamma-polyglutamic acid | |
| CN111893151A (en) | Method for continuously producing low molecular weight hyaluronic acid, low molecular weight hyaluronic acid obtained by method and application of low molecular weight hyaluronic acid | |
| JPH0630604B2 (en) | Hyaluronic acid manufacturing method | |
| CN115232226B (en) | Extraction method of external polysaccharide of Pantoea alhagi | |
| KR100312638B1 (en) | Method for manufacturing high purity hyaluronic acid | |
| Kanala et al. | Efficient recovery of hyaluronic acid from highly viscous culture broth | |
| JP2009284826A (en) | Method for producing hyaluronic acid | |
| JP3973312B2 (en) | Method for producing hyaluronic acid by fermentation | |
| JPH05276972A (en) | Production of hyaluronic acid | |
| Kanala et al. | Microbial production of high purity hyaluronic acid from Streptococcus zooepidemicus | |
| JPS63129991A (en) | Production of hyaluronic acid | |
| JPH04108395A (en) | Production of galactosamino-oligosaccharide | |
| JP2010057379A (en) | Method for producing hyaluronic acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20180613 |